These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 39095323

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
    Luo J, Cheng K, Ji X, Gao C, Zhu R, Chen J, Xue W, Huang Q, Xu Q.
    Cancer Lett; 2024 Jun 01; 591():216892. PubMed ID: 38621459
    [Abstract] [Full Text] [Related]

  • 3. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
    Xie P, Yu M, Zhang B, Yu Q, Zhao Y, Wu M, Jin L, Yan J, Zhou B, Liu S, Li X, Zhou C, Zhu X, Huang C, Xu Y, Xiao Y, Zhou J, Fan J, Hung MC, Ye Q, Guo L, Li H.
    J Hepatol; 2024 Jul 01; 81(1):93-107. PubMed ID: 38403027
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H, You T, Ge H, Gao J, Wang Y, Bai C, Sun Z, Han Q, Zhao RC.
    Int Immunopharmacol; 2024 May 30; 133():112053. PubMed ID: 38615380
    [Abstract] [Full Text] [Related]

  • 6. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.
    Hepatology; 2015 May 30; 61(5):1591-602. PubMed ID: 25529917
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.
    Zhu Y, Chen M, Xu D, Li TE, Zhang Z, Li JH, Wang XY, Yang X, Lu L, Jia HL, Dong QZ, Qin LX.
    Cell Mol Immunol; 2022 Jun 30; 19(6):726-737. PubMed ID: 35459855
    [Abstract] [Full Text] [Related]

  • 9. Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer.
    Ma J, Deng Y, Zhang M, Zhang Q.
    Immunology; 2024 Nov 30; 173(3):536-551. PubMed ID: 39078223
    [Abstract] [Full Text] [Related]

  • 10. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL.
    Theranostics; 2020 Nov 30; 10(23):10619-10633. PubMed ID: 32929370
    [Abstract] [Full Text] [Related]

  • 11. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma.
    Li Y, Li F, Xu L, Shi X, Xue H, Liu J, Bai S, Wu Y, Yang Z, Xue F, Xia Y, Dong H, Shen F, Wang K.
    Theranostics; 2024 Nov 30; 14(9):3526-3547. PubMed ID: 38948071
    [Abstract] [Full Text] [Related]

  • 12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, Tsai WB, Qiao Y, Yu B, Larrick JW, Hu MC.
    J Immunother Cancer; 2021 Dec 30; 9(12):. PubMed ID: 34887262
    [Abstract] [Full Text] [Related]

  • 13. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X, Zhou Y, Yokota Y, Matsumoto Y, Zhai B, Maarouf N, Hayashi H, Carlson R, Zhang S, Sousa A, Sun B, Ghanbari H, Dong X, Wands JR.
    J Exp Clin Cancer Res; 2022 Apr 08; 41(1):132. PubMed ID: 35392977
    [Abstract] [Full Text] [Related]

  • 14. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.
    Gastroenterology; 2017 Oct 08; 153(4):1107-1119.e10. PubMed ID: 28648905
    [Abstract] [Full Text] [Related]

  • 15. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L, Montironi C, Puigvehí M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, Piqué-Gili M, Torres-Martín M, Peix J, Geh D, Ramon-Gil E, Saberi B, Friedman SL, Mann DA, Sia D, Llovet JM.
    Hepatology; 2021 Nov 08; 74(5):2652-2669. PubMed ID: 34157147
    [Abstract] [Full Text] [Related]

  • 16. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.
    Chen H, Li Z, Qiu L, Dong X, Chen G, Shi Y, Cai L, Liu W, Ye H, Zhou Y, Ouyang J, Cai Z, Liu X.
    J Immunother Cancer; 2022 Sep 08; 10(9):. PubMed ID: 36113894
    [Abstract] [Full Text] [Related]

  • 17. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer.
    Yang Y, Li L, Jiang Z, Wang B, Pan Z.
    Cancer Immunol Immunother; 2020 Dec 08; 69(12):2523-2532. PubMed ID: 32577817
    [Abstract] [Full Text] [Related]

  • 18. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma.
    Huang Y, Peng M, Yu W, Li H.
    Int Immunopharmacol; 2024 Sep 10; 138():112534. PubMed ID: 38941667
    [Abstract] [Full Text] [Related]

  • 19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, Shan J, Shen J, Yang Z, Wang G, Zhou H, Prieto J, Ávila MA, Liu C, Qian C.
    Gastroenterology; 2020 Feb 10; 158(3):664-678.e24. PubMed ID: 31678303
    [Abstract] [Full Text] [Related]

  • 20. EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.
    Huang H, Zhu X, Yu Y, Li Z, Yang Y, Xia L, Lu S.
    J Transl Med; 2024 Jul 14; 22(1):653. PubMed ID: 39004699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.